Analysis of Bronchoalveolar Lavage Fluid from Bleomycin-Induced Pulmonary Fibrosis in Hamsters

Abstract

The purpose of this study was to analyze the cellular and noncellular components of bronchoalveolar lavage fluid (BALF) at varying times during the development of pulmonary fibrosis induced by bleomycin. Hamsters were killed and lavaged in situ following the administration of a single intratracheal injection of 1 unit of bleomycin or an equivalent volume of sterile isotonic saline. The results show that the total cell counts in the BALF of bleomycin-treated hamsters, as compared with controls, were increased 7.7, 4.4, 2.4, 1.6, and 1.9-fold at 2, 4, 7, 14, and 21 days after treatment, respectively. The predominant cell types in the BALF of control animals were macrophages which constituted 84% of the total cells, followed by lymphocytes, 11%. The predominant cell types in the BALF of bleomycin-treated animals were polymorphonuclear leukocytes (PMN) which constituted 65% at two days and approximately 50% of the total at 4, 7, and 14 days; at 21 days macrophages were the predominant cell type constituting 50%, followed by lymphocytes at 30%. However, the total number of lymphocytes was not increased at 21 days compared to previous times. The noncellular protein content of BALF from bleomycin-treated hamsters, an index of pulmonary vascular permeability, was increased to 224, 559, 637, and 270% of control (2.7 mg/lung) at 2, 4, 7, and 14 days after treatment, respectively, and returned to control levels at 21 days. The acid phosphatase activity in the supernatant of BALF of bleomycin-treated animals was significantly increased to 181, 181, 199, 176, and 125% of control (258 units/lung) at 2, 4, 7, 14, and 21 days, respectively. β-Glucuronidase activity in the supernatant of BALF of control hamsters was 64 units/lung, whereas in bleomycin-treated animals the activity was significantly increased to 226 units/lung at two days and that 161 units/lung at four days after treatment. Histamine content in the supernatant of BALF of bleomycin-treated animals was increased from a control value of 28 ng/lung to 41, 41, 59, 45 ng/lung at 2, 4, 7, and 14 days after treatment, respectively. There was no difference in the total prostaglandin E (PGE) content of the BALF-supernatant between control and bleomycin-treated hamsters. The data presented in this report demonstrate that the release of lysosomal enzymes and histamine may play a significant role in the pathogenesis of bleomycin-induced lung damage.

References

1. Adamson IYR and Bowden DH (1974). The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am. J. Pathol. 77: 185–198.

2. Blum RH , Carter SK , and Agre K (1973). A clinical review of bleomycin. A new antineoplastic agent. Cancer 31: 903–914.

3. Carane R , Schwade JG , Turrisi AT , Webber BL , and Muggia FM (1979). Pulmonary toxicity after radiation and bleomycin; a review. Int. J. Radiat. Oncol. Biol. Phys. 5: 1513–1518.

4. Carpo JD , Barry BE , Foscue HA , and Shelburne J (1980). Structural and biochemical changes in rat lungs occurring during exposures to lethal and adaptive doses of oxygen. Am. Rev. Respir. Dis. 122: 123–143.

5. Catravas JD , Lazo JS , Dobuler KJ , Mills LR , and Gillis CN (1983). Pulmonary endothelial dysfunction in the presence or absence of interstitial injury induced by intratracheally injected bleomycin in rabbits. Am. Rev. Respir. Dis. 128: 740–746.

6. Catravas JD , Lazo JS , and Gillis CN (1981). Biochemical markers of bleomycin toxicity: Clearance of 14C-5-hydroxytryptamine and 3H-norepinephrine by rabbit lung in vivo. J. Pharmacol. Exp. Ther. 217: 524–529.

7. Center DM (1983). Identification of rat mast cell-derived chemoattractant factors for lymphocytes. J. Allergy Clin. Immunol. 71: 29–35.

8. Chandler DB and Giri SN (1983). Changes in plasma concentrations of prostaglandins and plasma angiotensin-converting enzyme during bleomycin-induced lung fibrosis. Am. Rev. Respir. Dis. 128: 71–76.

9. Chandler DB , Hyde DM , and Giri SN (1983). Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am. J. Pathol. 112: 170–177.

10.

10. Crooke ST and Bradner WT (1976). Bleomycin, a review. J. Med. 7: 333–428.

11.

11. Crystal RG , Fulmer JD , Roberts WC , Moss ML , Line BR , and Reynolds NY (1976). Idiopathic pulmonary fibrosis, clinical, histologic, radiographic, physiologic, scintigraphic, cytologic and biochemical aspects. Ann. Intern. Med. 85: 769–788.

12.

12. Davis GS , Brody AR , and Craighead JE (1978). Analysis of air-space and interstitial mononuclear cell population in human diffuse interstitial lung disease. Am. Rev. Respir. Dis. 118: 7–15.

13.

13. DeNicola DB , Rebar AH , and Henderson RF (1981). Early damage indicators in the lung. V. Biochemical and cytological response to NO2 inhalation. Toxicol. Appl. Pharmacol. 60: 301–302.

14.

14. Diaz P , Jones DG , and Kay AB (1979). Histamine receptors on guinea-pig alveolar macrophages: Chemical specificity and the effects of H1- and H2-receptor agonists and antagonists. Clin. Exp. Immunol. 35: 462–469.

15.

15. Dixon WJ (1981). BMDP Statistical Software. University of California Press, Los Angeles, CA, pp. 1–725.

16.

16. Emau P , Giri SN , and Bruss ML (1984). Role of prostaglandins, histamine, and serotonin in the pathophysiology induced by Pasteurella hemolytica endotoxin in sheep. Circ. Shock 12: 47–59.

17.

17. Fahey PJ , Utell MJ , Mayewski RJ , Wandtke JD , and Hyde RW (1982). Early diagnosis of bleomycin pulmonary toxicity using bronchoalveolar lavage in dogs. Am. Rev. Respir. Dis. 126: 126–130.

18.

18. Fantone JC and Ward PA (1983). Mechanism of neutrophil-dependent lung injury. In: Immunology of Inflammation, PA Ward (ed). Elsevier Science Publishing Co., New York, pp. 89–120.

19.

19. Fox RB , Hoidal JR , Brown DM , and Repine JE (1981). Pulmonary inflammation due to oxygen toxicity: Involvement of chemotactic factors and polymorphonuclear leukocytes. Am. Rev. Respir. Dis. 123: 521–523.

20.

20. Gillis CN and Catravas JD (1982). Altered removal of vasoactive substances in the injured lung: Detection of lung microvascular injury. Ann. NY Acad. Sci. 384: 456–474.

21.

21. Giri SN , Hollinger MA , and Schiedt MJ (1981). The effects of paraquat and superoxide dismutase on pulmonary vascular permeability and edema in mice. Arch. Environ. Health 36: 149–154.

22.

22. Giri SN , Schwartz LW , Hollinger MA , Freywald ME , Schiedt MJ , and Zuckerman JE (1980). Biochemical and structural alterations of hamster lungs in response to intratracheal administration of bleomycin. Exp. Mol. Pathol. 33: 1–14.

23.

23. Giri SN and Witt TC (1985). Effects of intratracheal administration of bleomycin on various prostaglandins and thromboxane-B2 on collagen levels of the lung in hamster. Expt. Lung Res. 9: 119–133.

24.

24. Goldstein RH , Lucey EC , Franzblau C , and Snider GL (1979). Failure of mechanical properties to parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am. Rev. Respir. Dis. 120: 67–73.

25.

25. Goto T , Befus D , Low R , and Bienenstock J (1984). Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats. Am. Rev. Respir. Dis. 130: 797–802.

26.

26. Haslam PL , Turton CWG , Lukoszek A , et al (1980). Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosis alveolitis and their relation to therapy. Thorax. 35: 328–339.

27.

27. Henderson RF , Rebar AH , Pickrell JA , and Newton GJ (1979). Early damage indicatros in the lung. III. Biochemical and cytological response of the lung to inhaled metal salts. Toxicol. Appl. Pharmacol. 50: 123–136.

28.

28. Henson PM (1980). Mechanisms of exocytosis in phagocytic inflammatory cells. Am. J. Pathol. 101: 494–514.

29.

29. Ignarro LJ (1971). Effects of anti-inflammatory drugs on the stability of rat liver lysosomes in vitro. Biochem. Pharmacol. 20: 2847–2860.

30.

30. Kawanami O , Ferrans VJ , Fulmer JD , and Crystal RG (1979). Ultrastructure of pulmonary mast cells in patients with fibrotic lung disorders. Lab Invest. 40: 717–734.

31.

31. Kellogg EW and Fridovich I (1975). Superoxide, hydrogen peroxide and singlet oxygen in lipid peroxide by xanthine oxidase system. J. Biol. Chem. 250: 8812–8817.

32.

32. Lowry OH , Rosebrough NJ , Farr AL , and Randall RJ (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265–275.

33.

33. Martin WJ , Gadek JE , Humminghake GW , and Crystal RG (1981). Oxidant injury of lung parenchymal cells. J. Clin. Invest. 68: 1277–1288.

34.

34. Norrby K (1983). Intradermal mast-cell secretion causing cutaneous mitogenesis. Virchows Arch. (Cell Pathol.) 42: 263–269.

35.

35. Raisfeld IH (1980). Pulmonary toxicity of bleomycin analogs. Toxicol. Appl. Pharmacol. 56: 326–336.

36.

36. Reynolds HY , Fulmer JD , Kazmierowski JA , Roberts WC , Frank MM , and Crystal RG (1977). Analysis of cellular and protein content of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J. Clin. Invest. 59: 165–175.

37.

37. Sacs R , Moldow CF , Craddock PR , Bowers TK , and Jacob HS (1978). Oxygen radicals mediate endothelial cell damage by complement stimulated granulocytes: An in vitro model of immune vascular damage. J. Clin. Invest. 61: 1161–1167.

38.

38. Saltini C , Hance AJ , Ferrans VJ , Basset F , Bitterman PB , and Crystal RG (1984). Accurate quantitation of cells recovered by bronchoalveolar lavage. Am Rev. Respir. Dis. 130: 650–658.

39.

39. Samuelsson B (1983). Leukotriene: Mediators of immediate hypersensitivity reactions and inflammation. Science 220: 568–575.

40.

40. Seligman AM , Chauncey HH , Nachlas MM , Manheimer LH , and Ravin HA (1951). The colorimetric determination of phosphatases in human serum. J. Biol. Chem. 190: 7–15.

41.

41. Shore PA , Burkhalter A , and Cohn VH Jr. (1959). A method for the fluorometric assay of histamine in tissues. J. Pharmacol. Exp. Ther. 127: 182–186.

42.

42. Snider GL , Celli BR , Goldstein RH , O'Brien JJ , and Lucey EC (1978). Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Am. Rev. Respir. Dis. 117: 289–297.

43.

43. Snider GL , Hayes JA , and Korthy AL (1978). Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin. Am. Rev. Respir. Dis. 117: 1099–1108.

44.

44. Thrall RS , Barton RW , D'Amato DA , and Sulavik SB (1982). Differential cellular analysis of bronchoalveolar lavage fluid obtained at various stages during the development of bleomycin-induced pulmonary fibrosis in the rat. Am. Rev. Respir. Dis. 126: 488–492.

45.

45. Thrall RS , McCormack JR , Jack RM , McReynolds RA , and Ward PA (1979). Bleomycin-induced pulmonary fibrosis in the rat. Am. J. Pathol. 95: 117–127.

46.

46. Wangensteen D , Yankovich R , Hoidal J , and Niewoehner D (1983). Bleomycin-induced changes in pulmonary microvascular albumin permeability and extravascular albumin space. Am. Rev. Respir. Dis. 127: 204–208.

47.

47. Watanabe S , Watanabe K , Ohishi T , Aiba M , and Kageyama K (1974). Mast cells in the rat alveolar septa undergoing fibrosis after ionizing radiation, ultrastructural and histochemical studies. Lab. Invest. 31: 555–567.

48.

48. Weinberger SE , Kelman JA , Elson NA , Young RC , Reynolds HY , Fulmer JD , and Crystal RG (1978). Bronchoalveolar lavage in interstitial lung disease. Ann. Int. Med. 89: 459–466.